Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Eve vs TD Tele-Doc Weight Loss

Eve
Graded #189

Higher grade

vs+4.5
TD Tele-Doc Weight Loss
Graded #286

Lower grade

The verdict

Eve takes it — 66.3/100 to 61.8/100.

Eve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eve is a women's-health-focused GLP-1 telehealth platform — distinctive positioning in a largely gender-neutral market — offering both compounded semaglutide and tirzepatide (including an oral sublingual…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEve +10
55
45
Dose & formulationEve +35
88
53
Clinical oversightTD Tele-Doc Weight Loss +9
79
88
Labs & monitoringTD Tele-Doc Weight Loss +13
52
65
FulfillmentTD Tele-Doc Weight Loss +1
67
68
Contract termsTD Tele-Doc Weight Loss +14
41
55
Eve · left barTD Tele-Doc Weight Loss · right bar

The numbers

MetricEveTD Tele-Doc Weight Loss
WeighScore66.3/10061.8/100
GradeCC
Scorecard rank#189#286
Semaglutide$195/mo (compounded)Not disclosed
Tirzepatide$195/mo (compounded)Not disclosed
CoverageCoverage not published2 states
Brand-name accessYesYes
Oral / sublingualYesInjection only
Eve

Graded #189 · C

Strengths

  • Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
  • Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
  • LegitScript Certified with a verifiable ID
  • Publishes the FDA compounded-medication disclaimer
  • Oral sublingual semaglutide offered alongside injectable

Where it loses points

  • Full states-served list not disclosed publicly
  • 503A pharmacy partner not named, and 503A vs 503B status not specified
  • Named medical director / clinical leadership not disclosed
  • Corporate legal entity not disclosed
  • Governing law / arbitration venue not stated
TD Tele-Doc Weight Loss

Graded #286 · C

Strengths

  • Brand Wegovy/Zepbound AND compounded sema available; prescribing based on medical history and coverage
  • 100% virtual — weekly appointments with board-certified MDs from home; no travel required
  • Remote Patient Monitoring Starter Box: biometric scale + blood pressure cuff sync to care team in real time
  • In-network with most commercial insurance plans; may cover visits and monitoring equipment
  • Physician-led by Dr. Peter Wilbanks MD (30-yr OB/GYN, VCU) and Dr. Michael Perini MD (ABIM board-certified)

Where it loses points

  • No public cash pricing; cost entirely depends on insurance coverage — not viable for uninsured patients
  • Telehealth available only in Virginia and Maryland; no national reach confirmed
  • No Medicare or Medicaid accepted; limited to commercial insurance plans only
  • No LegitScript certification found; compounded availability and specific pricing undisclosed on site
  • Tirzepatide (Zepbound/Mounjaro) availability less prominent in MD pages; semaglutide is primary focus

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard